Subscribe to MDT Magazine News

Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h

October 21, 2010 8:32 am | by Bio-Medicine.Org | Comments

MORRISTOWN, N.J., Oct. 21 /- Actavis Inc. today announced a voluntary recall to the wholesale and retail levels only of 18 lots of Fentanyl Transdermal System 25 mcg/hour C-II patches manufactured for Actavis by Corium International in the United States. Actavis identified one lot of 25...


Forensic scientists use postmortem imaging-guided biopsy to determine natural causes of death

October 21, 2010 8:32 am | by EurekAlert | Comments

(American College of Radiology / American Roentgen Ray Society) Researchers found that the combination of computed tomography, postmortem CT angiography and biopsy can serve as a minimally invasive option for determining natural causes of death such as cardiac arrest, according to a study...


AACR Colorectal Cancer Conference to Focus on Screening, New Treatments

October 21, 2010 8:32 am | by AACR | Comments

PHILADELPHIA — The American Association for Cancer Research will hosts its first special conference on Colorectal Cancer: Biology to Therapy from Oct. 27-30, 2010, at the Loews Hotel, Philadelphia.


<i>Blog: </i>Ozzy Osbourne's DNA, way beyond the need to know

October 21, 2010 7:31 am | by Mass High Tech: The Journal of New England Technology | Comments

MHT Editor James M. Connolly blogs: Knome Inc., the Cambridge genomics company, completed a sequencing of Ozzy Osbourne’s genome. Now, Ozzy and Sharon plan to reveal the results of his test. It’s the technology equivalent of the old line, “You don’t really want to know how the sausages are made.”

Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics

October 21, 2010 5:34 am | by Bio-Medicine.Org | Comments

RICHMOND, Calif., Oct. 21 /- Lumiphore Inc., a biotechnology leader in new proprietary bifunctional metal-chelation technology for use in high-value imaging, diagnostics, and therapeutics and Algeta ASA (OSE:ALGETA), the cancer therapeutics company, announced that they have signed a...


Collagen Matrix, Inc. Expands Operations and Moves Corporate Headquarters to Oakland, New Jersey

October 21, 2010 5:33 am | by Bio-Medicine.Org | Comments

OAKLAND, N.J., Oct. 21 /- Collagen Matrix, Inc., the leader in collagen- and mineral-based matrix engineering, announced today that it is expanding its operations by the addition of a 28,000 sq. ft. facility at 15 Thornton Road, Oakland, New Jersey 07436. The company will be relocating...


Dental Implant Market in Canada Experiences 5.6% Growth in 2009 While US Market Declines by 4.2%

October 21, 2010 5:33 am | by Bio-Medicine.Org | Comments

TORONTO, Oct. 21 /- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, while Canada typically mimics US trends in the North American dental implant market, last year was very different. The struggling American economy led to a...


Boston Scientific Announces FDA Clearance and CE Mark Approval for Advanix™ Biliary Stents

October 21, 2010 5:31 am | by Boston Scientific | Comments

Latest innovation in plastic biliary stent technology includes features for enhanced deliverability, efficiency and procedural control


IDEV Technologies Launches Additional Products in Europe

October 21, 2010 3:34 am | by Bio-Medicine.Org | Comments

WEBSTER, Texas, Oct. 21 /- IDEV Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced another step in the implementation of its strategy to expand its product line for treating patients...


Danaher Reports Record Third Quarter 2010 Results

October 21, 2010 3:34 am | by Bio-Medicine.Org | Comments

WASHINGTON, Oct. 21 /- Danaher Corporation (NYSE: DHR ) announced today that GAAP net earnings for the quarter ended October 1, 2010 were $646.4 million, or $0.95 per diluted share, which includes a $0.34 gain related to the formation of the Apex Tool Group joint venture, and represents a...


DNA minivectors provide new gene therapy tool

October 21, 2010 3:33 am | by Baylor College of Medicine | Comments

Tiny wound-up circular bits of DNA that carry a short "hairpin" of RNA could prove a solution to the quest for a non-toxic, long-lived gene therapy vector designed to silence cancer genes in tumor cells, said researchers from Baylor College of Medicine and The Methodist Hospital Research...


Researchers develop first implanted device to treat balance disorder

October 21, 2010 3:32 am | by EurekAlert | Comments

(University of Washington) A University of Washington Medical Center patient on Thursday, Oct. 21, will be the world's first recipient of a device that aims to quell the disabling vertigo associated with Meniere's disease. The UW Medicine clinicians who developed the implantable device...


Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor

October 21, 2010 1:32 am | by Bio-Medicine.Org | Comments

LONDON, Oct. 21 /- Shionogi-ViiV Healthcare LLC today announced the start of the Phase III clinical programme evaluating its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572). The Phase III clinical programme, which began this month, includes two studies...


Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C

October 21, 2010 1:31 am | by Bio-Medicine.Org | Comments

VIENNA, Oct. 21 /- Intercell AG (VSE; "ICLL") and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half...


Freescale accelerates automotive safety with advanced airbag sensors

October 20, 2010 11:33 pm | by I-Micronews | Comments

Xtrinsic sensors support the DSI 2.5 protocol, providing a smaller footprint and reduced time to market for cost-effective passenger safety


You may login with either your assigned username or your e-mail address.
The password field is case sensitive.